Corcept Therapeutics (CORT) EPS (Basic) (2010 - 2026)

Corcept Therapeutics has reported EPS (Basic) for 17 years, with the latest figure at $0.4 in Q2 2026.

• Quarterly EPS (Basic) rose 20.29% year-over-year to $0.4 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $0.51 (down 59.42% YoY) and the FY2025 annual result came in at $0.95, down 30.17% from the prior year.
• EPS (Basic) climbed to $0.4 in Q2 2026 per CORT's latest filing, from -$0.3 in the prior quarter.
• Over five years, EPS (Basic) peaked at $0.45 in Q3 2024 and troughed at -$0.3 in Q1 2026.
• A 5-year average of $0.24 and a median of $0.27 in 2023 frame the typical range for EPS (Basic).
• The sharpest annual moves came in 2023 and 2026: EPS (Basic) surged 94.24% in 2023, then slumped 253.31% in 2026.
• Over 5 years, EPS (Basic) stood at $0.15 in 2022, then soared by 94.24% to $0.3 in 2023, then dropped by 2.11% to $0.29 in 2024, then declined by 21.82% to $0.23 in 2025, then soared by 73.76% to $0.4 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered $0.4, -$0.3, and $0.23 for Q2 2026, Q1 2026, and Q4 2025 respectively.